AML consolidation therapy: timing matters.

Area of Science:

• Hematology
• Oncology
• Pharmacology

Background:

• Severe neutropenia is a primary cause of mortality in acute myeloid leukemia (AML) patients undergoing therapy.
• Novel strategies are crucial to mitigate neutropenia's severity and duration in AML treatment.

Purpose of the Study:

• To compare the efficacy of cytarabine administration schedules (AC-123 vs. AC-135) in AML consolidation therapy.
• To evaluate the impact of different cytarabine dosages, G-CSF administration, and cycle lengths on neutropenia recovery.

Main Methods:

• Analysis of 334 treatment schedules using virtual cohorts of digital twins.
• Simulation of over 32,565 consolidation cycles comparing AC-123 and AC-135 regimens.
• Assessment of white blood cell (WBC) recovery time and leukemic blast counts.

Main Results:

• AC-123 significantly reduced WBC recovery time by a median of 3.5 days in 99.6% of simulated cycles compared to AC-135.
• The AC-123 regimen showed a lower or equal number of leukemic blasts in 94.2% of cycles.
• These findings held true across various cytarabine dosages, G-CSF use, and cycle lengths.

Conclusions:

• The AC-123 schedule, combined with G-CSF, is supported by numerical studies for AML consolidation.
• This approach can effectively reduce the duration of neutropenia, thereby lowering the risk of life-threatening infections.
• AC-123 plus G-CSF represents a promising standard for conventional AML consolidation therapy.